GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Tangible Book per Share

TNF Pharmaceuticals (LTS:0A8D) Tangible Book per Share : $-0.26 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is TNF Pharmaceuticals Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. TNF Pharmaceuticals's tangible book value per share for the quarter that ended in Mar. 2025 was $-0.26.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


TNF Pharmaceuticals Tangible Book per Share Historical Data

The historical data trend for TNF Pharmaceuticals's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TNF Pharmaceuticals Tangible Book per Share Chart

TNF Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Tangible Book per Share
-4.25 10.35 3.08 0.86 -0.25

TNF Pharmaceuticals Quarterly Data
Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -4.45 2.48 -0.25 -0.26

Competitive Comparison of TNF Pharmaceuticals's Tangible Book per Share

For the Biotechnology subindustry, TNF Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TNF Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TNF Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where TNF Pharmaceuticals's Price-to-Tangible-Book falls into.


;
;

TNF Pharmaceuticals Tangible Book per Share Calculation

TNF Pharmaceuticals's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(14.72-5.075-10.499)/3.364
=-0.25

TNF Pharmaceuticals's Tangible Book Value Per Share for the quarter that ended in Mar. 2025 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(13.842-5.296-10.499)/7.393
=-0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


TNF Pharmaceuticals  (LTS:0A8D) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


TNF Pharmaceuticals Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of TNF Pharmaceuticals's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TNF Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1185 Avenue of the Americas, Suite 249, New York, NY, USA, 10036
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.

TNF Pharmaceuticals Headlines

No Headlines